HC Wainwright & Co. Maintains Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has maintained a Buy rating on Longboard Pharmaceuticals (NASDAQ:LBPH) with a $60 price target. This reaffirms the firm's positive outlook on the stock.
March 15, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Longboard Pharmaceuticals with a $60 price target, indicating a strong positive outlook on the stock.
The maintenance of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100